Open Government Portal
MaintenanceWe are performing scheduled maintenance from 8:00am to 12:00pm, Monday, December 4th, Eastern time.
Listing of therapeutic products with paediatric information available in their labelling
The purpose of this document is to recommend international standards for, and promote harmonisation of, the nonclinical safety studies recommended to support human clinical trials of a given scope and duration as well as marketing authorization for pharmaceuticals.
Responding to the Opioid Crisis and Other Emergency Situations.
Medical batteries are medical devices and are regulated under the Food and Drugs Act and Medical Devices Regulations. The Act and Regulations govern the import, advertising and sale of medical devices in Canada.
The term Medical Devices, as defined in the Food and Drugs Act, covers a wide range of health or medical instruments used in the treatment, mitigation, diagnosis or prevention of a disease or abnormal physical condition.
Health Canada has successfully completed the transition to the Medical Device Single Audit Program (MDSAP). All manufacturers holding medical device licences in Canada now participate in the program, which improves Health Canada's oversight of the medical devices sold in Canada, and ensures that the medical devices Canadians use meet higher quality standards.
A growing number of Canadians are using medical test kits in their homes to diagnose or monitor certain health conditions. These test kits are considered to be medical devices. Like all medical devices, they provide potential benefits, but they can also present risks.
This guidance document provides medical device stakeholders with information on the requirements that the Therapeutics Products Directorate will use in recognizing Auditing Organizations under the MDSAP.
This guidance document applies to drugs regulated under Part C, Division 1 of the Regulations that have received a DIN pursuant to Section C.01.014.2. This includes pharmaceuticals for human and veterinary use, as well as disinfectant drugs, but excludes biologics and radiopharmaceuticals and any drug that has received an NOC.
Since 2016, under Guide BB of the Filing Manual, major CER-regulated pipeline companies are required to report their pipelines’ throughput and capacity data at key points every quarter. Oil and liquids pipelines report monthly data and natural gas pipelines report daily data. This dataset can be explored in interactive dashboard format: A look at pipeline flow and capacity. Throughput and capacity graphs can also be explored by individual pipeline in Pipeline Profiles. The dataset covers 2006 to present. Files are updated quarterly but may be refreshed as needed.